参考文献 (References)[1] H. G. Kopp, S. Patel, B. Brücher, et al. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma. American Journal of Clinical Dermatology, 2008, 9(4): 207-217.
[2] A. I. Spira, D. S. Ettinger. The use of chemotherapy in softtissue sarcomas. Oncologist, 2002, 7(4): 348-359.
[3] B. Kasper, T. Gil, V. D’Hondt, et al. Novel treatment strategies for soft tissue sarcoma. Critical Reviews in Oncology Hematology, 2007, 62(1): 9-15.
[4] S. P. Balcerzak, J. Benedetti, G. R. Weiss, et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A southwest oncology group study. Cancer, 1995, 76(11): 2248- 2252.
[5] W. J. Köstler, T. Brodowicz, Y. Attems, et al. Docetaxel as rescue medication in anthracyclineand ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: Results of a phase II trial. Annals of Oncology, 2001, 12(9): 1281-1288.
[6] I. Judson. Randomised phase IItrial of pegylated liposomal doxorubicin versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma. European Journal of Cancer, 2001, 37(7): 870-877.
[7] J. T. Hartmann, F. Mayer, J. Schleicher, et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer, 2007, 110(4): 861-866.
[8] J. Fayette, I. R. Coquard, L. Alberti, et al. ET-743: A novel agent with activity in soft tissue sarcomas. Oncologist, 2005, 10(10): 827-832.
[9] R. M. O’Bryan, L. H. Baker, J. E. Gottlieb, et al. Dose response evaluation of adriamycin in human neoplasia. Cancer, 1977, 39(5): 1940-1948.
[10] V. H. Bramwell, D. Anderson, M. L. Charette, et al. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database of Systems Reviews, 2003, 3: Article ID CD003293.
[11] A. Santoro, T. Tursz, H. Mouridsen, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European organization for research and treatment of cancer soft tissue and bone sarcoma group. Journal of Clinical Oncology, 1995, 13(7): 1531-1533.
[12] S. Verma, J. Younus, D. Stys-Norman, et al. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Reviews, 2008, 34(4): 339-347.
[13] V. Bramwell, D. Anderson and M. Charette. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: A metaanalysis and clinical practice guideline. Sarcoma, 2000, 4(3): 103-112.
[14] P. Lorigan, J. Verweij, Z. Papai, et al. Phase III trial of two investigational schedules of ifosfamide compared with standarddose doxorubicin in advanced or metastatic soft tissue sarcoma: A European organisation for research and treatment of cancer soft tissue and bone sarcoma group study. Journal of Clinical Oncology, 2007, 25(21): 3144-3150.
[15] J. Maurel, A. López-Pousa, R. de Las Peñas, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: An open-label randomized phase II study of the Spanish group for research on sarcomas. Journal of Clinical Oncology, 2009, 27(11): 1893-1898.
[16] P. Dileo, J. A. Morgan, D. Zahrieh, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: Results of a phase II trial. Cancer, 2007, 109(9): 1863-1869.
[17] V. Bramwell, M. Blackstein, K. Belanger, et al. A Phase II Study of docetaxel in chemotherapy-naïve patients with recurrent or metastatic adult soft tissue sarcoma. Sarcoma. 1998, 2(1): 29-33.
[18] R. G. Maki, J. K. Wathen, S. R. Patel, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: Results of sarcoma alliance for research through collaboration study 002 [corrected]. Journal of Clinical Oncology, 2007, 25(19): 2755- 2763.
[19] J. Verweij, P. G. Casali, J. Zalcberg, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet, 2004, 364(9440): 1127-1134.
[20] D. R. D’Adamo, S. E.Anderson, K. Albritton, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. Journal of Clinical Oncology, 2005, 23(8): 7135-7142.
[21] B. Kasper. Standards and novel therapeutic options in the treatment of patients with soft tissue sarcoma. Reviews on Recent Clinical Trials, 2007, 2(3): 206-211.
[22] S. R. Grobmyer, R. G. Maki, G. D. Demetri, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Annals of Oncology, 2004, 15(11): 1667-1672.
[23] F. C. Eilber, G. Rosen, J. Eckardt, et al. Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. Journal of Clinical Oncology, 2001, 19(13): 3203-3209.
[24] T. F. DeLaney, I. J. Spiro, H. D. Suit, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. International Journal of Radiation on Oncology * Biology * Physics, 2003, 56(4): 1117-1127.
[25] W. G. Kraybill, J. Harris, I. J. Spiro, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation therapy oncology group trial 9514. Journal of Clinical Oncology, 2006, 24(4): 619-625.
[26] M. A. Mohagheghi, S. Sadighi, J. Raafat, et al. Neoadjuvant chemotherapy with Ifosfamide, Cisplatin, Adriamycin and Mitomycin (IMAP) for high risk adult soft tissue sarcomas. Acta Medica Iranica, 2009, 47(2): 133-138.
[27] E. Gortzak, A. Azzarelli, J. Buesa, et al. A randomised phase II study on neo-adjuvant chemotherapy for “high-risk” adult softtissue sarcoma. European Journal of Cancer, 2001, 37(9): 1096- 1103.
[28] S. Steen, G. Stephenson. Current treatment of soft tissue sarcoma. Proceedings (Baylor University Medical Center), 2008, 21(4): 392-396.
[29] Sarcoma meta analysis collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: metaanalysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet, 1997, 350(9092): 1647-1654.
[30] P. G. Casali, P. Picci. Adjuvant chemotherapy for soft tissue sarcoma. Current Opinion in Oncology, 2005, 17(4): 361-365.
[31] A. Figueredo, V. H. Bramwell, R. Bell, et al. Adjuvant chemotherapy following complete resection of soft tissue sarcoma in adults: A clinical practice guideline. Sarcoma, 2002, 6(1): 5-18.
[32] N. Pervaiz, N. Colterjohn, F. Farrokhyar, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer, 2008, 113(3): 573-581.
[33] F. C. Eilber, M. F. Brennan, F. R. Eilber, et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Annals of Surgery, 2007, 246(1): 105-113.
[34] A. Italiano, N. Penel, Y. M. Robin, et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: A study of the French Sarcoma Group. Annals of Oncology, 2009, 20(3): 425-430.
[35] P. J. Woll, M. V. Glabbeke, P. Hohenberger, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial. 2007 ASCO Annual Meeting Proceedings Part I. 25(18S), June 20 Supplement, 2007: 10008.
[36] F. C. Eilber, F. R. Eilber, J. Eckardt, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Annals of Surgery, 2004, 240(4): 686-697.
[37] M. M. Zalupski, L. H. Baker. Systemic adjuvant chemotherapy for soft tissue sarcomas. Hematology/Oncology Clinics of North America, 1995, 9(4): 787-800.
[38] J. T. Hartmann, S. Patel. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs, 2005, 65(2): 167-178.
[39] R. Palumbo, S. Palmeri and M. Antimi. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Annals of Oncology, 1997, 8(11): 1159-1162.
[40] V. Karavasilis, B. M. Seddon, S. Ashley, et al. Significant clinical benefit of first-line palliative chemotherapy in advanced softtissue sarcoma: Retrospective analysis and identification of prognostic factors in 488 patients. Cancer, 2008, 112(7): 1585-1591.
[41] C. R. Rossi, M. Deraco, M. De Simone, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: Clinical outcome and prognostic factors in 60 consecutive patients. Cancer, 2004, 100(9): 1943-1950.
[42] F. J. Lejeune, D. Liénard, M. Matter, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immunity, 2006, 22(6): 6.
[43] D. J. Grünhagen, J. H. de Wilt, T. L. ten Hagen, et al. Technology insight: Utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities. Nature Clinical Practice Oncology, 2006, 3(2): 94-103.
[44] G. Taeger, F. Grabellus, L. E. Podleska, et al. Effectiveness of regional chemotherapy with TNF-α/Melphalan in advanced soft tissue sarcoma of the extremities. International Journal of Hyperthermia, 2008, 24(4): 193-203.
[45] A. Misra, N. Mistry, R. Grimer, et al. The management of soft tissue sarcoma. Journal of Plastic, Reconstructive & Aesthetic Surgery, 2009, 62(2): 161-174.
[46] M. Verma, J. Younus, D. Stys-Norman, et al. Dose-Intensive chemotherapy with growth factor or autologous bone marrow/ stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma. Cancer, 2008, 112(6): 1197- 1205.